Nash D.
262
Coauthors
7
Documentos
Volumen de publicaciones por año
Cargando gráfico
Año de publicación | Num. Publicaciones |
---|---|
2018 | 1 |
2021 | 2 |
2022 | 4 |
Publicaciones por áreas de conocimiento
Cargando gráfico
Área de conocimiento | Num. Publicaciones |
---|---|
Infección | 4 |
Epidemiología | 4 |
Salud pública | 2 |
Salud Pública | 2 |
Estudios de género | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
Área temática | Num. Publicaciones |
---|---|
Problemas sociales y servicios a grupos | 5 |
Enfermedades | 5 |
Medicina y salud | 4 |
Programación informática, programas, datos, seguridad | 1 |
Ginecología, obstetricia, pediatría, geriatría | 1 |
Fuerzas aéreas y otras fuerzas especializadas | 1 |
Medicina forense; incidencia de enfermedades | 1 |
Principales fuentes de datos
Origen | Num. Publicaciones |
---|---|
Scopus | 7 |
Google Scholar | 0 |
RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
Coautor | Num. Publicaciones |
---|---|
Matthew L. Romo | 7 |
Kulkarni S.G. | 3 |
Wools-Kaloustian K.K. | 3 |
Brazier E. | 3 |
Kelvin E.A. | 3 |
Murenzi G. | 3 |
Lelo P. | 3 |
Kochhar S. | 2 |
You W. | 2 |
Zimba R. | 2 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Onchocerciasis and epilepsy: a causal relationship?
OtherAbstract:Palabras claves:Autores:Matthew L. Romo, Nash D.Fuentes:scopusDeterminants and Trends of COVID-19 Vaccine Hesitancy and Vaccine Uptake in a National Cohort of US Adults: A Longitudinal Study
ArticleAbstract: We estimated the trends and correlates of vaccine hesitancy and its association with subsequent vaccPalabras claves:Covid-19 pandemic, COVID-19 vaccine racial/ethnic disparities, COVID-19 vaccine uptake, Longitudinal cohort study, vaccine delay, Vaccine hesitancy, vaccine hesitancy trends, vaccine refusalAutores:Berry A., Chang M., Grov C., Kochhar S., Kulkarni S.G., Maroko A.R., Matthew L. Romo, Nash D., Parcesepe A.M., Poehlein E., Rane M.S., Robertson M.M., Westmoreland D.A., You W., Zimba R.Fuentes:scopusPatterns of SARS-CoV-2 Testing Preferences in a National Cohort in the United States: Latent Class Analysis of a Discrete Choice Experiment
ArticleAbstract: Background: Inadequate screening and diagnostic testing in the United States throughout the first sePalabras claves:cohort, covid-19, diagnostic, discrete choice, Discrete Choice Experiment, latent class analysis, pattern, Preference, PUBLIC HEALTH, SARS-COV-2, TESTING, transmission, trend, UNITED STATES, Uptake, VaccineAutores:Berry A., Grov C., Kochhar S., Kulkarni S.G., Maroko A.R., Matthew L. Romo, Mirzayi C., Nash D., Parcesepe A.M., Rane M.S., Robertson M.M., Waldron L., Westmoreland D.A., You W., Zimba R.Fuentes:scopusViral Load Status Before Switching to Dolutegravir-Containing Antiretroviral Therapy and Associations With Human Immunodeficiency Virus Treatment Outcomes in Sub-Saharan Africa
ArticleAbstract: Background: Dolutegravir is being rolled out globally as part of preferred antiretroviral therapy (APalabras claves:antiretroviral agents, clinical decision-making, HIV integrase inhibitors, prognosis, Viral loadAutores:Diero L., Edwards J.K., Kasozi C., Kelvin E.A., Lelo P., Matthew L. Romo, Murenzi G., Musick B.S., Nash D., Odhiambo F., Semeere A.S., Sohn A.H., Urassa M., Wools-Kaloustian K.K., Wyka K.Fuentes:scopusReal-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa
ArticleAbstract: Introduction: Dolutegravir is being scaled up globally as part of antiretroviral therapy (ART), butPalabras claves:antiretroviral agents, antitubercular agents, drug interactions, HIV integrase inhibitors, Observational Study, rifampinAutores:Brazier E., Chimbetete C., De Waal R., Diero L., Dzudie A., Ezechi O.C., Fenner L., Kunzekwenyika C., Lelo P., Mahambou-Nsondé D., Matthew L. Romo, Muhairwe J.A., Murenzi G., Muyindike W.R., Nash D., Rafael I., Sekaggya-Wiltshire C., Shah N.S., Tiendrebeogo T., Twizere C., Wools-Kaloustian K.K., Yotebieng M.Fuentes:scopus